Trial Search Results

Radical-Dose Image Guided Radiation Therapy in Treating Patients With Metastatic Non-small Cell Lung Cancer Undergoing Immunotherapy

This phase II trial studies how well radical-dose image guided radiation therapy works in treating patients with non-small cell lung cancer that has spread to other places in the body who are undergoing immunotherapy. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving radical-dose image guided radiation therapy to patients with non-small cell lung cancer may help to improve response to immunotherapy anti-cancer treatment.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Stanford University


  • Biological: Immunotherapy (standard of care)
  • Radiation: Image Guided Radiation Therapy
  • Other: Laboratory Biomarker Analysis


Phase 2


Inclusion Criteria:

   - Has metastatic non-small cell lung cancer (NSCLC)

   - Has been receiving anti-PD-1 or anti-PD-L1 immunotherapy for at least four weeks

   - Has had restaging imaging after initiation of immunotherapy, at least 4 weeks after
   pre-immunotherapy baseline imaging; computed tomography (CT) or positron emission
   tomography (PET)/CT of at least chest/upper abdomen must be performed within 4 weeks
   prior to registration; for patients with history of brain metastases, brain magnetic
   resonance imaging (MRI) or CT is required within 4 weeks of registration; for other
   patients brain MRI or CT is required within 12 weeks of registration

   - Is expected by the treating medical oncologist to continue on immunotherapy for at
   least three more months; imaging must show response, stable disease, or modest
   progression as determined by the treating medical oncologist; if there is modest
   progression, the patient must be clinically stable in terms of performance status and
   overall disease-related symptoms

   - Has at least one extracranial tumor safely treatable with radical-dose radiation

   - Eastern Cooperative Oncology Group (ECOG) performance status 0-2

   - Has the ability to understand and the willingness to sign a written informed consent

Exclusion Criteria:

   - Untreated brain metastases, if not planned to be treated in this course of radiation

   - Pregnancy or women of childbearing potential not willing/able to use contraception
   during protocol treatment

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Kim Nguyen